These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 24422724

  • 1. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, Conter V, Biondi A, Cazzaniga G, Valsecchi MG.
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [Abstract] [Full Text] [Related]

  • 2. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A.
    J Clin Oncol; 2013 Jul 20; 31(21):2736-42. PubMed ID: 23775972
    [Abstract] [Full Text] [Related]

  • 3. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer; 2013 Apr 20; 49(6):1346-55. PubMed ID: 23265714
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert MH, Willasch AM, Klingebiel TE, Peters C.
    J Clin Oncol; 2015 Apr 10; 33(11):1275-84. PubMed ID: 25605857
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 10; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 9. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ.
    Ann Hematol; 2012 Feb 20; 91(2):183-92. PubMed ID: 21710165
    [Abstract] [Full Text] [Related]

  • 10. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J.
    Pediatr Blood Cancer; 2007 Jan 20; 48(1):93-100. PubMed ID: 16521130
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
    Pochon C, Oger E, Michel G, Dalle JH, Salmon A, Nelken B, Bertrand Y, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rohrlich P, Paillard C, Demeocq F, Schneider P, Plantaz D, Poirée M, Eliaou JF, Semana G, Drunat S, Jonveaux P, Bordigoni P, Gandemer V.
    Br J Haematol; 2015 Apr 20; 169(2):249-61. PubMed ID: 25522886
    [Abstract] [Full Text] [Related]

  • 13. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
    Shi XL, Tang XW, Wei XA, Zhao BR, Zhou QL, Ye F, Lu YX, Sun XW, Zhu MQ, Shen WH, Qiu HY, Sun AN, Wu DP.
    Zhonghua Yi Xue Za Zhi; 2011 Oct 18; 91(38):2692-6. PubMed ID: 22321979
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 18; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE.
    Leukemia; 1995 Oct 18; 9(10):1726-34. PubMed ID: 7564517
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D.
    Leukemia; 2004 Mar 18; 18(3):499-504. PubMed ID: 14981525
    [Abstract] [Full Text] [Related]

  • 18. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ, Tang YM, Song H, Shi SW, Yang SL, Shen HQ, Wei J, Xu WQ, Pan BH, Zhao FY.
    Zhonghua Er Ke Za Zhi; 2010 Mar 18; 48(3):180-4. PubMed ID: 20426951
    [Abstract] [Full Text] [Related]

  • 19. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
    Ruggeri A, Michel G, Dalle JH, Caniglia M, Locatelli F, Campos A, de Heredia CD, Mohty M, Hurtado JM, Bierings M, Bittencourt H, Mauad M, Purtill D, Cunha R, Kabbara N, Gluckman E, Labopin M, Peters C, Rocha V.
    Leukemia; 2012 Dec 18; 26(12):2455-61. PubMed ID: 22555150
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR.
    Lancet; 1998 Nov 28; 352(9142):1731-8. PubMed ID: 9848348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.